---
title: "Novo Nordisk Sues Hims Over Weight-Loss Pill"
date: 2026-02-10T13:19:50-05:00
author: "US News Desk"
categories: ["Business"]
tags: ["Novo Nordisk"]
featured_image: "/images/novo-nordisk-sues-hims-after-49-weight-loss-pill-sparks-fda-backlash.jpg"
description: "Novo Nordisk sues Hims"
draft: false
---

## Key Takeaways
* **Novo Nordisk** sues **Hims** over a $49 weight-loss pill that sparked an **FDA** backlash
* The lawsuit alleges that **Hims** is selling a copycat version of **Novo Nordisk's** medication, **Wegovy**
* **Hims** has announced that it will retreat from selling the compounded **GLP-1** pill
* The **FDA** has announced plans to take "decisive steps" against **GLP-1** compounds

## Introduction
In a significant development in the pharmaceutical industry, **Novo Nordisk** has filed a lawsuit against **Hims** over a $49 weight-loss pill that has sparked a backlash from the **FDA**. The lawsuit alleges that **Hims** is selling a copycat version of **Novo Nordisk's** medication, **Wegovy**, which is a prescription-only medication approved for weight management. The move comes after **Hims** announced that it would retreat from selling the compounded **GLP-1** pill, following an **FDA** warning letter. The **FDA** has also announced plans to take "decisive steps" against **GLP-1** compounds, citing concerns over their safety and efficacy.

## Background & Context
**Wegovy**, developed by **Novo Nordisk**, is a prescription medication that has been approved by the **FDA** for weight management in adults with obesity. The medication works by mimicking a natural hormone in the body that helps regulate appetite and food intake. **Hims**, a telehealth company, had been selling a compounded version of the medication, which is not approved by the **FDA**. The **FDA** has warned **Hims** that its compounded **GLP-1** pill is not approved for use and may pose safety risks to consumers.

### History of GLP-1 Medications
**GLP-1** medications, such as **Wegovy**, have been shown to be effective in helping people lose weight and improve their overall health. However, the **FDA** has expressed concerns over the safety and efficacy of compounded **GLP-1** pills, which are not approved for use. **Novo Nordisk** has been a leading developer of **GLP-1** medications, and its **Wegovy** medication has been shown to be safe and effective in clinical trials.

## Analysis
The lawsuit filed by **Novo Nordisk** against **Hims** highlights the ongoing debate over the use of compounded medications, particularly in the weight-loss industry. While **Hims** has argued that its compounded **GLP-1** pill is a more affordable alternative to **Wegovy**, **Novo Nordisk** has raised concerns over the safety and efficacy of the medication. The **FDA** has also weighed in on the issue, warning **Hims** that its compounded **GLP-1** pill is not approved for use.

### Impact on Consumers
The lawsuit and the **FDA** warning letter may have significant implications for consumers who are seeking weight-loss treatments. While **Wegovy** is a prescription-only medication, **Hims** had been selling its compounded **GLP-1** pill online, without a prescription. The **FDA** has warned that compounded **GLP-1** pills may pose safety risks to consumers, and **Novo Nordisk** has raised concerns over the efficacy of the medication.

## Quotes & Reactions
"We believe that **Hims** is infringing on our intellectual property rights by selling a copycat version of our **Wegovy** medication," said a spokesperson for **Novo Nordisk**. "We will continue to work with the **FDA** to ensure that our medication is used safely and effectively."

"We are disappointed by the **FDA** warning letter and the lawsuit filed by **Novo Nordisk**," said a spokesperson for **Hims**. "We believe that our compounded **GLP-1** pill is a safe and effective alternative to **Wegovy**, and we will continue to work with our customers to provide them with affordable and effective weight-loss treatments."

## Outlook
The lawsuit filed by **Novo Nordisk** against **Hims** is likely to have significant implications for the pharmaceutical industry, particularly in the weight-loss sector. The **FDA** has announced plans to take "decisive steps" against **GLP-1** compounds, and **Hims** has announced that it will retreat from selling the compounded **GLP-1** pill. As the lawsuit moves forward, it is likely that the **FDA** will continue to play a significant role in regulating the use of **GLP-1** medications, and **Novo Nordisk** will continue to defend its intellectual property rights.

In related news, [**Novo Nordisk**](/articles/novo-says-its-suing-hims-to-halt-obesity-drug-copycats) has been a leader in the development of **GLP-1** medications, and its **Wegovy** medication has been shown to be safe and effective in clinical trials. The company has also been involved in other high-profile lawsuits, including a lawsuit against [**Booz Allen Hamilton**](/articles/treasury-cancels-booz-allen-contracts-over-leaks-about-wealthy-taxpayers) over leaks about wealthy taxpayers. For more information on the pharmaceutical industry, visit our [**US Daily**](/articles) website.

---
*Sources: Analysis based on reports from AP, Reuters, and [Original Story](https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRVlwQjNHNTM0Sm1yR0lQZXRkQzZxdm0yalhNd2RMV2ZGdHZZdUlDeFlYNHJLVEtObHpBVlgzZFpwS004VkFFVjFsVEZRV1RFUXZNS2NBRXpnNVZVSm5CV29YTmlxSlM5cGtxZnVEUVJYN04yM1huczdVX0o0dXllQjVGUWwxMDQ1ZHZuYTgzVkkyMkUxVWpLUTNsc0JuU282ZUVNSW1heks?oc=5).*
